Syndax Pharmaceuticals (SNDX) Gross Profit (2024 - 2026)

Syndax Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at $53.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 176.76% year-over-year to $53.0 million; the TTM figure through Mar 2026 stood at $213.2 million (up 407.56% YoY), while the FY2025 annual figure was $165.4 million, up 623.65% from the prior year.
• Gross Profit for Q1 2026 stood at $53.0 million, down from $85.9 million in the prior quarter.
• The five-year high for Gross Profit was $85.9 million in Q4 2025, with the low at $3.5 million in Q2 2024.
• The 3-year median for Gross Profit is $27.9 million (2025), against an average of $31.9 million.
• The sharpest annual moves came in 2025 and 2026: Gross Profit jumped 1153.92% in 2025, then soared 176.76% in 2026.
• Syndax Pharmaceuticals' Gross Profit stood at $6.9 million in 2024, then surged by 1153.92% to $85.9 million in 2025, then sank by 38.31% to $53.0 million in 2026.
• Business Quant data shows SNDX's Gross Profit at $53.0 million in Q1 2026, $85.9 million in Q4 2025, and $37.6 million in Q3 2025.